Pharma BD Deal Intelligence
A $5.4B acquisition that gave Eli Lilly full ownership of Novartis Animal Health, expanding Lilly's veterinary business (Elanco) at scale. The deal carried no disclosed upfront breakdown or named pipeline assets, leaving the strategic rationale largely a bet on animal health as a growth adjacency.
Lilly acquired Novartis Animal Health for $5.4B.
Eli Lilly completed its $5.4 billion acquisition of Novartis Animal Health, adding nine manufacturing sites, six R&D facilities, 600 products, and more than…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Lilly acquired Novartis Animal Health for $5.4B.
$24.0B Global Animal Health Market (2014) · $3.5B Combined Elanco Revenue (post-merger)
Eli Lilly acquired Novartis's animal health division for $5.4B as part of the broader 2014 Novartis portfolio reshaping. The deal doubled Lilly's Elanco animal health business, adding companion animal parasiticides (Sentinel, Program), livestock products, and vaccines. This positioned Elanco as the #2 global animal health company behind Zoetis.
The animal health market was consolidating rapidly in 2014-2015. Zoetis (spun from Pfizer in 2013) was the market leader. Merck Animal Health and Boehringer Ingelheim's Merial were major competitors. Lilly's $5.4B bet expanded Elanco significantly, and the company was eventually spun off as an independent public company in 2018 at ~$14B valuation, later acquiring Bayer Animal Health in 2020.
Lilly to acquire Novartis Animal Health for $5.4B to strengthen Elanco. Part of Eli Lilly and Company's $5.4B deal to acquire Novartis Animal Health.
Eli Lilly and Company completed its acquisition of Novartis Animal Health for $5.4B. Lilly acquired Novartis Animal Health for $5.4B.
Lilly spun off Elanco via IPO at $24/share. Stock soared 40% on first day. Part of Eli Lilly and Company's $5.4B deal to acquire Novartis Animal Health.
Exchange offer completed, making Elanco fully independent public company. Part of Eli Lilly and Company's $5.4B deal to acquire Novartis Animal Health.
See timeline for full assessment. Assessment of Eli Lilly and Company's $5.4B acquisition of Novartis Animal Health and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Novartis Animal Health (this deal) | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |